Summary:
In patients with ischemic heart disease (IHD), combination therapy of statins, SGLT2 inhibitors, and PCSK9 inhibitors significantly reduced lipid parameters (-74±10 mg/dL, p<0.05) compared to monotherapy groups (statins, SGLT2 inhibitors, PCSK9 inhibitors alone), though it was associated with minor modulation in response due to age and gender.
| PICO | Description |
|---|---|
| Population | Adults (N=500) diagnosed with ischemic heart disease (IHD), enrolled from multiple centers for a 12-month randomized controlled trial. |
| Intervention | Combination therapy consisting of statins, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. |
| Comparison | Monotherapy groups receiving either statins alone, SGLT2 inhibitors alone, or PCSK9 inhibitors alone. |
| Outcome | All treatment arms showed lipid reduction, but the combination group achieved the highest mean reduction in lipid levels (-74±10 mg/dL, p<0.05). Age and gender slightly influenced therapeutic responses. |
Source: Mohammad, N., et al. “The Impact of Disease-Modifying Medications on the Lipid Profile of Patients with Ischemic Heart Disease.” Georgian Med News. Read article here.
